This inventor holds 21 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Imperial Chemical Industries Limited, Pfizer Corporation. Active years: 1984-1995.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Woodnesborough, GB (1985)
- Deal, GB (1988)
- Sandwich, GB (1984 - 1990)
- Congleton, GB (1990 - 1995)
Company Filing History:
11 out of 3,840 
10 out of 4,488 
Years Active: 1984-1995
Areas of Expertise:
Title: David A. Roberts: Innovator in Pharmaceutical Chemistry
Introduction
David A. Roberts is a distinguished inventor based in Congleton, GB, with a remarkable portfolio of 21 patents. His groundbreaking innovations predominantly focus on the development of novel pharmaceutical compounds aimed at treating significant health conditions, including hypertension and congestive heart failure.
Latest Patents
Two of his latest patents showcase his expertise in pharmaceutical chemistry. The first patent, titled "Quinoline derivatives and use thereof as angiotensin II antagonists," involves pharmaceutically useful novel compounds which hold potential for a variety of medical applications. These compounds, alongside their non-toxic salts and pharmaceutical compositions, are designed to effectively treat conditions such as hypertension and congestive heart failure. The patent further outlines processes for the manufacture of these compounds and their use in medical treatments.
His second patent is for "Pyridine compounds which have useful pharmaceutical utility." This innovation also focuses on pharmaceutically useful compounds, revealing their various applications in treating similar health conditions. Like the first, it discusses the synthesis and therapeutic application of these compounds, emphasizing their importance in contemporary medicine.
Career Highlights
Throughout his career, David A. Roberts has made significant contributions while working with leading companies in the pharmaceutical industry, notably Imperial Chemical Industries Limited and Pfizer Corporation. His extensive experience in these organizations has allowed him to drive innovations that impact patient care and treatment methodologies significantly.
Collaborations
David has collaborated with notable peers in his field, including Simon F. Campbell and Robert Hugh Bradbury. These partnerships have likely enriched his work and facilitated advancements in pharmaceutical research and development.
Conclusion
David A. Roberts exemplifies the spirit of innovation in the field of pharmaceutical chemistry. His numerous patents highlight his contributions to medical science, particularly in the realm of hypertension and heart failure treatments. As the pharmaceutical industry continues to evolve, his work sets a remarkable precedent for future developments in this vital sector.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile